T3 Pharmaceuticals AG’s CHF19.3 Million Series C Financing Round

VISCHER advises T3 Pharmaceuticals AG on all legal issues related to the transaction. T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech advancing immuno-oncology with its bacteria-based…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Paolo Bossi

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here